When did Lexaria Bioscience report Q4 2025 earnings?

Lexaria Bioscience (LEXX) reported Q4 2025 earnings on January 13, 2026 before market open.

What were Lexaria Bioscience's Q4 2025 revenue and EPS?

Lexaria Bioscience reported diluted EPS of $-0.07 for Q4 2025.

EPS beat the consensus estimate of $-0.13 by $0.06.

Compared to the same quarter a year prior, diluted EPS grew 56.3% from $-0.16.

You can read the 10-Q periodic report (0001640334-26-000080) directly on SEC EDGAR. The filing index links above go to sec.gov.

Reported January 13, 2026 · Before market open

Revenue estimate$100.0K

EPS estimate-$0.13

Jul 13, 2026 (In 3 weeks)

Revenue estimate$50.0K

EPS estimate-$0.06

Q4 2025-$0.07Beat by $0.06

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

When did Lexaria Bioscience report Q4 2025 earnings?: Lexaria Bioscience (LEXX) reported Q4 2025 earnings on January 13, 2026 before market open.
What were Lexaria Bioscience's Q4 2025 revenue and EPS?: Lexaria Bioscience reported diluted EPS of $-0.07 for Q4 2025.
Did Lexaria Bioscience beat estimates in Q4 2025?: EPS beat the consensus estimate of $-0.13 by $0.06.
How did Lexaria Bioscience's Q4 2025 results compare year-over-year?: Compared to the same quarter a year prior, diluted EPS grew 56.3% from $-0.16.
Where can I find Lexaria Bioscience's Q4 2025 SEC filings?: You can read the 10-Q periodic report (0001640334-26-000080) directly on SEC EDGAR. The filing index links above go to sec.gov.